Regeneron Pharmaceuticals Inc (REGN)vsSurrozen Inc (SRZN)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
SRZN
Surrozen Inc
$25.00
-0.95%
HEALTHCARE · Cap: $215.57M
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 397872% more annual revenue ($14.34B vs $3.60M). REGN leads profitability with a 31.4% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
SRZN
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Intrinsic value data unavailable for SRZN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : SRZN
The strongest argument for SRZN centers on Debt/Equity.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : SRZN
The primary concerns for SRZN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
SRZN carries more volatility with a beta of 0.56 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (58/100 vs 24/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Surrozen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Surrozen Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address severe diseases, leveraging its proprietary SIRPa-IgG platform for targeted immune response modulation. The company's robust pipeline includes groundbreaking antibody therapeutics primarily aimed at oncology and autoimmune disorders, reflecting its commitment to fulfilling significant unmet medical needs. Bolstered by strategic partnerships and a strong emphasis on research and development, Surrozen is strategically positioned to advance transformative therapies, marking it as a promising player within the biopharmaceutical landscape with substantial growth potential.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?